sars cov  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
    Name:
    Human SARS Coronavirus Spike Insect Cell Lysate
    Description:
    Baculovirus Insect Cell lysate that Human SARS Coronavirus Spike Receptor Binding Domain transfected overexpressed for Western blot WB positive control The whole cell lysate is provided in 1X Sample Buffer 1X modified RIPA buffer 1X SDS loading buffer
    Catalog Number:
    40150-v08b2l
    Product Aliases:
    SARS coronavirus s1 Overexpression Lysate, SARS coronavirus s2 Overexpression Lysate, SARS coronavirus spike Overexpression Lysate, SARS cov spike Overexpression Lysate, SARS ncov RBD Overexpression Lysate, SARS ncov s1 Overexpression Lysate, SARS ncov s2 Overexpression Lysate, SARS ncov spike Overexpression Lysate, SARS novel coronavirus RBD Overexpression Lysate, SARS novel coronavirus s1 Overexpression Lysate, SARS novel coronavirus s2 Overexpression Lysate, SARS novel coronavirus spike Overexpression Lysate, SARS RBD Overexpression Lysate, SARS S1 Overexpression Lysate, SARS s2 Overexpression Lysate, SARS Spike RBD Overexpression Lysate
    Price:
    195
    Applications:
    WB
    Size:
    300µg
    Category:
    Lysate
    Cell Type:
    Baculovirus-Insect cells
    		Buy from Supplier

    Structured Review

    Sino Biological sars cov
    Neutralizing activity of convalescent sera from <t>SARS</t> patients against <t>SARS-CoV</t> and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p
    Baculovirus Insect Cell lysate that Human SARS Coronavirus Spike Receptor Binding Domain transfected overexpressed for Western blot WB positive control The whole cell lysate is provided in 1X Sample Buffer 1X modified RIPA buffer 1X SDS loading buffer
    https://www.bioz.com/result/sars cov/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov - by Bioz Stars, 2021-02
    93/100 stars

    Related Products / Commonly Used Together

    rna
    vero e6 cells
    pbs
    cdna
    mers-cov
    hcov-oc43
    pcr
    human angiotensin-converting enzyme 2
    pet11a
    rt-pcr
    vero cells
    bpu 1102
    restriction sites nde i
    costar 96-well black microplates
    tev protease cleavage sites

    Images

    1) Product Images from "Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals"

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    Journal: bioRxiv

    doi: 10.1101/2020.04.20.052126

    Neutralizing activity of convalescent sera from SARS patients against SARS-CoV and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p
    Figure Legend Snippet: Neutralizing activity of convalescent sera from SARS patients against SARS-CoV and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p

    Techniques Used: Activity Assay, Infection

    Sequence comparison between the RBDs of SARS-CoV and SARS-CoV-2. (A) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV-2 strain IPBCAMS-WH-01 (designated SARS2). (B) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV strain GD03T0013. Conservative and non-conservative mutations are marked in blue and red, respectively.
    Figure Legend Snippet: Sequence comparison between the RBDs of SARS-CoV and SARS-CoV-2. (A) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV-2 strain IPBCAMS-WH-01 (designated SARS2). (B) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV strain GD03T0013. Conservative and non-conservative mutations are marked in blue and red, respectively.

    Techniques Used: Sequencing

    Cross-reactive and neutralizing activities of antisera from mice immunized with a full-length S protein of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S, S1, RBD, and S2) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Cross-reactive and neutralizing activities of antisera from mice immunized with a full-length S protein of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S, S1, RBD, and S2) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Mouse Assay, Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactivity and neutralization of purified rabbit anti-RBD antibodies. (A) Binding titers of purified rabbit anti-RBD antibodies to SARS-CoV (RBD) and SARS-CoV-2 (S, RBD, and S2) antigens were determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing titers of purified rabbit anti-RBD antibodies on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations.
    Figure Legend Snippet: Cross-reactivity and neutralization of purified rabbit anti-RBD antibodies. (A) Binding titers of purified rabbit anti-RBD antibodies to SARS-CoV (RBD) and SARS-CoV-2 (S, RBD, and S2) antigens were determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing titers of purified rabbit anti-RBD antibodies on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations.

    Techniques Used: Neutralization, Purification, Binding Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactive and neutralizing activities of antisera from mice immunized with RBD proteins of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Cross-reactive and neutralizing activities of antisera from mice immunized with RBD proteins of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Mouse Assay, Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactivity of convalescent sera from SARS-CoV infected patients with SARS-CoV-2 determined by ELISA. (A) Reactivity of sera from 20 recovered SARS-CoV patients (P01 to P20) with the nucleoprotein (N) of SARS-CoV-2 was measured by a commercial ELISA kit. (B) Reactivity of convalescent SARS sera with the recombinant S1 and RBD proteins of SARS-CoV. (C) Reactivity of convalescent SARS sera with the S ectodomain (designated S), S1, RBD, and S2 proteins of SARS-CoV-2. Serum samples from two healthy donors were used as negative control (Ctrl-1 and Ctrl-2). The experiments were performed with duplicate samples and repeated three times, and data are shown as means with standard deviations.
    Figure Legend Snippet: Cross-reactivity of convalescent sera from SARS-CoV infected patients with SARS-CoV-2 determined by ELISA. (A) Reactivity of sera from 20 recovered SARS-CoV patients (P01 to P20) with the nucleoprotein (N) of SARS-CoV-2 was measured by a commercial ELISA kit. (B) Reactivity of convalescent SARS sera with the recombinant S1 and RBD proteins of SARS-CoV. (C) Reactivity of convalescent SARS sera with the S ectodomain (designated S), S1, RBD, and S2 proteins of SARS-CoV-2. Serum samples from two healthy donors were used as negative control (Ctrl-1 and Ctrl-2). The experiments were performed with duplicate samples and repeated three times, and data are shown as means with standard deviations.

    Techniques Used: Infection, Enzyme-linked Immunosorbent Assay, Recombinant, Negative Control

    Cross-reactive and neutralizing activities of antisera from rabbits immunized with the RBD proteins of SARS-CoV. (A) Binding activity of rabbit antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing activity of rabbit antisera or control serum at indicated dilutions on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Cross-reactive and neutralizing activities of antisera from rabbits immunized with the RBD proteins of SARS-CoV. (A) Binding activity of rabbit antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing activity of rabbit antisera or control serum at indicated dilutions on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Inhibition of purified rabbit anti-RBD antibodies on the binding of RBD to 293T/ACE2 cells. (A) Blocking activity of rabbit anti-RBD antibodies on the binding of SARS-CoV RBD (upper panel) or SARS-CoV-2 RBD (lower panel) to 293T/ACE2 cells was determined by flow cytometry. (B) Purified rabbit anti-RBD antibodies inhibited the RBD-ACE2 binding does-dependently. The experiments repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Inhibition of purified rabbit anti-RBD antibodies on the binding of RBD to 293T/ACE2 cells. (A) Blocking activity of rabbit anti-RBD antibodies on the binding of SARS-CoV RBD (upper panel) or SARS-CoV-2 RBD (lower panel) to 293T/ACE2 cells was determined by flow cytometry. (B) Purified rabbit anti-RBD antibodies inhibited the RBD-ACE2 binding does-dependently. The experiments repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Inhibition, Purification, Binding Assay, Blocking Assay, Activity Assay, Flow Cytometry

    2) Product Images from "Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals"

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    Journal: bioRxiv

    doi: 10.1101/2020.04.20.052126

    Neutralizing activity of convalescent sera from SARS patients against SARS-CoV and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p
    Figure Legend Snippet: Neutralizing activity of convalescent sera from SARS patients against SARS-CoV and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p

    Techniques Used: Activity Assay, Infection

    Sequence comparison between the RBDs of SARS-CoV and SARS-CoV-2. (A) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV-2 strain IPBCAMS-WH-01 (designated SARS2). (B) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV strain GD03T0013. Conservative and non-conservative mutations are marked in blue and red, respectively.
    Figure Legend Snippet: Sequence comparison between the RBDs of SARS-CoV and SARS-CoV-2. (A) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV-2 strain IPBCAMS-WH-01 (designated SARS2). (B) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV strain GD03T0013. Conservative and non-conservative mutations are marked in blue and red, respectively.

    Techniques Used: Sequencing

    Cross-reactive and neutralizing activities of antisera from mice immunized with a full-length S protein of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S, S1, RBD, and S2) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Cross-reactive and neutralizing activities of antisera from mice immunized with a full-length S protein of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S, S1, RBD, and S2) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Mouse Assay, Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactivity and neutralization of purified rabbit anti-RBD antibodies. (A) Binding titers of purified rabbit anti-RBD antibodies to SARS-CoV (RBD) and SARS-CoV-2 (S, RBD, and S2) antigens were determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing titers of purified rabbit anti-RBD antibodies on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations.
    Figure Legend Snippet: Cross-reactivity and neutralization of purified rabbit anti-RBD antibodies. (A) Binding titers of purified rabbit anti-RBD antibodies to SARS-CoV (RBD) and SARS-CoV-2 (S, RBD, and S2) antigens were determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing titers of purified rabbit anti-RBD antibodies on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations.

    Techniques Used: Neutralization, Purification, Binding Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactive and neutralizing activities of antisera from mice immunized with RBD proteins of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Cross-reactive and neutralizing activities of antisera from mice immunized with RBD proteins of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Mouse Assay, Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactivity of convalescent sera from SARS-CoV infected patients with SARS-CoV-2 determined by ELISA. (A) Reactivity of sera from 20 recovered SARS-CoV patients (P01 to P20) with the nucleoprotein (N) of SARS-CoV-2 was measured by a commercial ELISA kit. (B) Reactivity of convalescent SARS sera with the recombinant S1 and RBD proteins of SARS-CoV. (C) Reactivity of convalescent SARS sera with the S ectodomain (designated S), S1, RBD, and S2 proteins of SARS-CoV-2. Serum samples from two healthy donors were used as negative control (Ctrl-1 and Ctrl-2). The experiments were performed with duplicate samples and repeated three times, and data are shown as means with standard deviations.
    Figure Legend Snippet: Cross-reactivity of convalescent sera from SARS-CoV infected patients with SARS-CoV-2 determined by ELISA. (A) Reactivity of sera from 20 recovered SARS-CoV patients (P01 to P20) with the nucleoprotein (N) of SARS-CoV-2 was measured by a commercial ELISA kit. (B) Reactivity of convalescent SARS sera with the recombinant S1 and RBD proteins of SARS-CoV. (C) Reactivity of convalescent SARS sera with the S ectodomain (designated S), S1, RBD, and S2 proteins of SARS-CoV-2. Serum samples from two healthy donors were used as negative control (Ctrl-1 and Ctrl-2). The experiments were performed with duplicate samples and repeated three times, and data are shown as means with standard deviations.

    Techniques Used: Infection, Enzyme-linked Immunosorbent Assay, Recombinant, Negative Control

    Cross-reactive and neutralizing activities of antisera from rabbits immunized with the RBD proteins of SARS-CoV. (A) Binding activity of rabbit antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing activity of rabbit antisera or control serum at indicated dilutions on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Cross-reactive and neutralizing activities of antisera from rabbits immunized with the RBD proteins of SARS-CoV. (A) Binding activity of rabbit antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing activity of rabbit antisera or control serum at indicated dilutions on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Inhibition of purified rabbit anti-RBD antibodies on the binding of RBD to 293T/ACE2 cells. (A) Blocking activity of rabbit anti-RBD antibodies on the binding of SARS-CoV RBD (upper panel) or SARS-CoV-2 RBD (lower panel) to 293T/ACE2 cells was determined by flow cytometry. (B) Purified rabbit anti-RBD antibodies inhibited the RBD-ACE2 binding does-dependently. The experiments repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.
    Figure Legend Snippet: Inhibition of purified rabbit anti-RBD antibodies on the binding of RBD to 293T/ACE2 cells. (A) Blocking activity of rabbit anti-RBD antibodies on the binding of SARS-CoV RBD (upper panel) or SARS-CoV-2 RBD (lower panel) to 293T/ACE2 cells was determined by flow cytometry. (B) Purified rabbit anti-RBD antibodies inhibited the RBD-ACE2 binding does-dependently. The experiments repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Techniques Used: Inhibition, Purification, Binding Assay, Blocking Assay, Activity Assay, Flow Cytometry

    Related Articles

    Recombinant:

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals
    Article Snippet: .. A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China). ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • sars cov  (Sino Biological)
    93
    Sino Biological sars cov
    Neutralizing activity of convalescent sera from <t>SARS</t> patients against <t>SARS-CoV</t> and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p
    Sars Cov, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov - by Bioz Stars, 2021-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Neutralizing activity of convalescent sera from SARS patients against SARS-CoV and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Neutralizing activity of convalescent sera from SARS patients against SARS-CoV and SARS-CoV-2 determined by single-cycle infection assay. (A) Neutralizing activity of convalescent patient sera was tested at a 1:20 dilution. Statistical significance was tested by two-way ANOVA with Dunnett posttest, indicating that all the sera significantly inhibited SARS-CoV and SARS-CoV-2 (p

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Activity Assay, Infection

    Sequence comparison between the RBDs of SARS-CoV and SARS-CoV-2. (A) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV-2 strain IPBCAMS-WH-01 (designated SARS2). (B) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV strain GD03T0013. Conservative and non-conservative mutations are marked in blue and red, respectively.

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Sequence comparison between the RBDs of SARS-CoV and SARS-CoV-2. (A) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV-2 strain IPBCAMS-WH-01 (designated SARS2). (B) RBD comparison of the palm civet SARS-CoV strain SZ16 and the human SARS-CoV strain GD03T0013. Conservative and non-conservative mutations are marked in blue and red, respectively.

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Sequencing

    Cross-reactive and neutralizing activities of antisera from mice immunized with a full-length S protein of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S, S1, RBD, and S2) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Cross-reactive and neutralizing activities of antisera from mice immunized with a full-length S protein of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S, S1, RBD, and S2) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Mouse Assay, Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactivity and neutralization of purified rabbit anti-RBD antibodies. (A) Binding titers of purified rabbit anti-RBD antibodies to SARS-CoV (RBD) and SARS-CoV-2 (S, RBD, and S2) antigens were determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing titers of purified rabbit anti-RBD antibodies on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations.

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Cross-reactivity and neutralization of purified rabbit anti-RBD antibodies. (A) Binding titers of purified rabbit anti-RBD antibodies to SARS-CoV (RBD) and SARS-CoV-2 (S, RBD, and S2) antigens were determined by ELISA. A healthy rabbit serum was tested as control. (B) Neutralizing titers of purified rabbit anti-RBD antibodies on SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were done in triplicates and repeated three times, and data are shown as means with standard deviations.

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Neutralization, Purification, Binding Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactive and neutralizing activities of antisera from mice immunized with RBD proteins of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Cross-reactive and neutralizing activities of antisera from mice immunized with RBD proteins of SARS-CoV. (A) Binding activity of mouse antisera at a 1:100 dilution to SARS-CoV (S1 and RBD) and SARS-CoV-2 (S protein and RBD) antigens was determined by ELISA. A healthy mouse serum was tested as control. (B) Neutralizing activity of mouse antisera at indicated dilutions against SARS-CoV, SARS-CoV-2, and VSV-G pseudoviruses was determined by a single-cycle infection assay. The experiments were performed in triplicates and repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Mouse Assay, Binding Assay, Activity Assay, Enzyme-linked Immunosorbent Assay, Infection

    Cross-reactivity of convalescent sera from SARS-CoV infected patients with SARS-CoV-2 determined by ELISA. (A) Reactivity of sera from 20 recovered SARS-CoV patients (P01 to P20) with the nucleoprotein (N) of SARS-CoV-2 was measured by a commercial ELISA kit. (B) Reactivity of convalescent SARS sera with the recombinant S1 and RBD proteins of SARS-CoV. (C) Reactivity of convalescent SARS sera with the S ectodomain (designated S), S1, RBD, and S2 proteins of SARS-CoV-2. Serum samples from two healthy donors were used as negative control (Ctrl-1 and Ctrl-2). The experiments were performed with duplicate samples and repeated three times, and data are shown as means with standard deviations.

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Cross-reactivity of convalescent sera from SARS-CoV infected patients with SARS-CoV-2 determined by ELISA. (A) Reactivity of sera from 20 recovered SARS-CoV patients (P01 to P20) with the nucleoprotein (N) of SARS-CoV-2 was measured by a commercial ELISA kit. (B) Reactivity of convalescent SARS sera with the recombinant S1 and RBD proteins of SARS-CoV. (C) Reactivity of convalescent SARS sera with the S ectodomain (designated S), S1, RBD, and S2 proteins of SARS-CoV-2. Serum samples from two healthy donors were used as negative control (Ctrl-1 and Ctrl-2). The experiments were performed with duplicate samples and repeated three times, and data are shown as means with standard deviations.

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Infection, Enzyme-linked Immunosorbent Assay, Recombinant, Negative Control

    Inhibition of purified rabbit anti-RBD antibodies on the binding of RBD to 293T/ACE2 cells. (A) Blocking activity of rabbit anti-RBD antibodies on the binding of SARS-CoV RBD (upper panel) or SARS-CoV-2 RBD (lower panel) to 293T/ACE2 cells was determined by flow cytometry. (B) Purified rabbit anti-RBD antibodies inhibited the RBD-ACE2 binding does-dependently. The experiments repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Journal: bioRxiv

    Article Title: Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

    doi: 10.1101/2020.04.20.052126

    Figure Lengend Snippet: Inhibition of purified rabbit anti-RBD antibodies on the binding of RBD to 293T/ACE2 cells. (A) Blocking activity of rabbit anti-RBD antibodies on the binding of SARS-CoV RBD (upper panel) or SARS-CoV-2 RBD (lower panel) to 293T/ACE2 cells was determined by flow cytometry. (B) Purified rabbit anti-RBD antibodies inhibited the RBD-ACE2 binding does-dependently. The experiments repeated three times, and data are shown as means with standard deviations. Statistical significance was tested by two-way ANOVA with Dunnett posttest.

    Article Snippet: A panel of recombinant proteins with a C-terminal polyhistidine (His) tag, including S1 and RBD of SARS-CoV (GenBank: AAX16192.1) and S ectodomain (S-ecto), S1, RBD, and S2 of SARS-CoV-2 (GenBank: YP_009724390.1), were purchased from the Sino Biological Company (Beijing, China).

    Techniques: Inhibition, Purification, Binding Assay, Blocking Assay, Activity Assay, Flow Cytometry